MedTrace Logo

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

NCT04949828 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2024-03-28

No results posted yet for this study

Summary

Exocrine Pancreatic Insufficiency (EPI) is a condition where pancreatic enzyme quantity or activity is reduced below threshold needed for normal digestion. Symptoms include bloating, flatulence, diarrhea and steatorrhea. This is an observational study assessing for effect of CREON on symptoms of EPI in participants with EPI due to chronic pancreatitis.

Conditions

  • Chronic Pancreatitis

Interventions

DRUG

CREON

Oral Capsules

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC. · AbbVie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-16
Primary Completion
2024-02-29
Completion
2024-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04949828 on ClinicalTrials.gov